Only colon cancer patients with Dukes stage C benefit from adjuvant chemotherapy with 5-fluorouracil and levamisole among 425 patients with operable colorectal cancer in a Norwegian randomised study
Dahl, O.; Tveit, K.M.; Carlsen, E.; Wiig, J.N.; Myrvold, H.E.; Gauperaa, T.; Skarstein, A.; Podhorny, N.; Bjerkeset, O.; Eide, T.J.
EJC Suppls 1(5): S324
2003
DOI: 10.1016/s1359-6349(03)91110-4
Accession: 035428625
PDF emailed within 0-6 h: $19.90
Related References
Moertel, C.G.; Fleming, T.R.; Macdonald, J.S.; Haller, D.G.; Laurie, J.A.; Tangen, C.M.; Ungerleider, J.S.; Emerson, W.A.; Tormey, D.C.; Glick, J.H. 1995: Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 13(12): 2936-2943Au, E.; Ang, P.T.; Seow-Choen, F.; Soo, K.C.; Low, C.H.; Chng, H.C.; Ng, B.K. 1998: Adjuvant chemotherapy for patients with resected Dukes' C and high-risk B2 colon cancer with fluorouracil and levamisole Annals of the Academy of Medicine Singapore 27(5): 733-737
Dencausse, Y.; Hartung, G.; Sturm, J.; Kopp-Schneider, A.; Hagmüller, E.; Wojatschek, C.; Lindemann, H.; Fritze, D.; Queisser, W. 2002: Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin Onkologie 25(5): 426-430
Dencausse, Y.; Hartung, G.; Sturm, J.; Kopp-Schneider, A.; Hagmüller, E.; Wojatschek, C.; Lindemann, H.; Fritze, D.; Queisser, W. 2002: Adjuvant Chemotherapy in Stage Iii Colon Cancer with 5-Fluorouracil and Levamisole versus 5-Fluorouracil and Leucovorin Oncology Research and Treatment 25(5): 426-430
Yamada, H.; Iinuma, H.; Watanabe, T. 2008: Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy Oncology Reports 19(3): 729-735
Wong, A.; Chan, A. 1996: Adjuvant chemotherapy after resection of stage III colon cancer Is fluorouracil/folinic acid as effective as levamisole/fluorouracil? Clinical and Investigative Medicine 19(4 Suppl): S59
Focan, C.; Bury, J.; Beauduin, M.; Herman, M.L.; Vindevoghel, A.; Lecomte, M.; Brohée, D.; Canon, J.L.; Focan-Henrard, D. 2000: Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer Anticancer Research 20(6c): 4665-4672
Kerr, D.J.; Gray, R.; McConkey, C.; Barnwell, J. 2000: Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group Annals of Oncology: Official Journal of the European Society for Medical Oncology 11(8): 947-955
Bleeker, W.A.; Mulder, N.H.; Hermans, J.; Otter, R.; Plukker, J.T. 2000: The addition of low-dose leucovorin to the combination of 5-fluorouracil- levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. IKN Colon Trial Group Annals of Oncology: Official Journal of the European Society for Medical Oncology 11(5): 547-552
Cascinu, S.; Catalano, V.; Piga, A.; Mattioli, R.; Marcellini, M.; Pancotti, A.; Bascioni, R.; Torresi, U.; Silva, R.R.; Pieroni, V.; Giorgi, F.; Catalano, G.; Cellerino, R. 2003: The role of levamisole in the adjuvant treatment of stage IIi colon cancer patients: a randomized trial of 5-fluorouracil and levamisole versus 5-fluorouracil alone Cancer Investigation 21(5): 701-707
Quasar Collaborative Group 2000: Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trial Lancet (North American Edition) 355(9215): 1588-1596
Poplin, E.A.; Benedetti, J.K.; Estes, N.C.; Haller, D.G.; Mayer, R.J.; Goldberg, R.M.; Weiss, G.R.; Rivkin, S.E.; Macdonald, J.S. 2005: Phase IIi Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage IIi and high-risk stage Ii colon cancer Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23(9): 1819-1825
Bleeker, W.A.; Mulder, N.H.; Hermans, J.; Otter, R.; Plukker, J.T.; Ikn, C.T.G. 2000: The addition of low-dose leucovorin to the combination of 5-fluorouracil-levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer Annals of Oncology 11(5): 547-552
Dahl, O.; Fluge, Øystein.; Carlsen, E.; Wiig, J.N.; Myrvold, H.E.; Vonen, B.; Podhorny, N.; Bjerkeset, O.; Eide, T.Jack.; Halvorsen, T.B.; Tveit, K.Magne. 2009: Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group Acta Oncologica 48(3): 368-376
Focan, C.; Bury, J.; Matus, G.; Graas, M.P.; Kreutz, F.; Longree, L.; Moeneclaey, N.; David, A.; Focanhenrard, D. 2005: Chimiothérapie adjuvante pour le cancer du colon de stades Dukes B2 et C comportant du 5-fluorouracile et de l'acide folinique, avec ou sans carboplatine. Faisabilité et comparaison d'une administration standard à une administration chronomodulée - Adjuvant chemotherapy for Dukes B2 and C colon cancer combining 5-fluorouracil and folinic acid with or without carboplatin. Feasibility and comparison between standard and chronomodulated deliveries Pathologie et Biologie 53(5): 281-284
Norum, J.; Vonen, B.; Olsen, J.A.; Revhaug, A. 1997: Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. a cost-effectiveness analysis Annals of Oncology: Official Journal of the European Society for Medical Oncology 8(1): 65-70
2004: Adjuvant chemotherapy with oxaliplatin, in combination with fluorouracil plus leucovorin prolongs disease-free survival, but causes more adverse events in people with stage II or III colon cancer Abstracted from: Andre T, Boni C, Mounedji-Boudiaf L, et al. Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant Cancer treatment reviews 30(8): 711-713
Schippinger, W.; Samonigg, H.; Schaberl-Moser, R.; Greil, R.; Thödtmann, R.; Tschmelitsch, J.; Jagoditsch, M.; Steger, G.G.; Jakesz, R.; Herbst, F.; Hofbauer, F.; Rabl, H.; Wohlmuth, P.; Gnant, M.; Thaler, J. 2007: A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer British Journal of Cancer 97(8): 1021-1027
Wolmark, N.; Rockette, H.; Mamounas, E.; Jones, J.; Wieand, S.; Wickerham, D.L.; Bear, H.D.; Atkins, J.N.; Dimitrov, N.V.; Glass, A.G.; Fisher, E.R.; Fisher, B. 1999: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04 Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(11): 3553-3559
Hafström, L.; Domellöf, L.; Rudenstam, C.M.; Norryd, C.; Bergman, L.; Nilsson, T.; Hansson, K.; Wählby, L.; Asklöf, G.; Kugelberg, C. 1990: Adjuvant chemotherapy with 5-fluorouracil, vincristine and CCNU for patients with Dukes' C colorectal cancer. the Swedish Gastrointestinal Tumour Adjuvant Therapy Group British Journal of Surgery 77(12): 1345-1348